06/03 Taiwan Life Sciences Weekly Newsletter
2025-06-03 |
| Taiwan Life Sciences Weekly |
| Formosa Pharmaceuticals signs licensing agreement with Adalvo for European and Brazilian markets 28 May, 2025 Formosa Pharmaceuticals (TW: 6838) announced that it has signed an exclusive licensing agreement with Adalvo Limited, granting the company the exclusive commercialization rights in the European and Brazilian markets for its new drug APP13007 (Clobetasol Propionate Ophthalmic Suspension 0.05 percent), developed for inflammation and pain relief after ocular surgery. More... (in Chinese) |
| Pharmosa Biopharm deepens focus on two core products 28 May, 2025 Pharmosa Biopharm (TW: 6875) during its recent shareholders' meeting stated that in 2025 global development of its two core products, L606 and L608, will continue to advance, with the company’s advantage in drug-device integration further expanding. L608 is expected to be formally submitted to the US FDA in the second half of the year for a Phase II clinical trial targeting systemic sclerosis-related Raynaud’s phenomenon and digital ulcers (SSc-RP/DU). A second Phase I clinical trial has already commenced in New Zealand and is expected to complete enrollment this year. More... (in Chinese) |
| Taiwan hosts international symposium to explore potentials of therapeutic biomolecules 27 May, 2025 Taiwan's National Biotechnology Research Park (NBRP) hosted the 2025 Antibody Therapeutic & Frontiers in Biomedical Sciences Conference on May 26-27. Designed to accelerate next-generation biomedical breakthroughs, the event serves as a forum for sharing research and establishing meaningful collaborations. This conference strengthened its role as a platform for fostering academic-industry collaboration and sharing cutting-edge biomedical knowledge. Academia Sinica Biomedical Translation Research Center (BioTReC), Taiwan Antibody Association (TAA), and Taipei Professor Lin Rongyao Academic Education Foundation co-organized the event. More... |
| GlycoNex announces publication of research Involving Pro-Antibody, GNX201 in the International Journal of Biological Macromolecules Press release 27 May, 2025 GlycoNex, Inc. (TW: 4168), a clinical stage biotechnology company focused on the development of glycan-directed cancer immunotherapies, today announced the publication of a peer-reviewed study in the International Journal of Biological Macromolecules (309, 143176) involving a prototype of GNX201 (L-HKM4). More... |
| National Taiwan University Hospital fully deploys pancreatic cancer imaging AI 26 May, 2025 National Taiwan University Hospital has recently launched a new AI-powered diagnostic imaging service for pancreatic cancer. Offered as a self-pay service at the NTUH Department of Medical Imaging since late 2024, it features an AI system touted as the first of its kind in the world. The PANCREASaver, which the hospital developed with the Institute of Applied Mathematical Sciences at National Taiwan University, leverages deep learning algorithms and a multi-image training dataset to automatically analyse CT scans, delineate the pancreas, and flag suspicious lesions. The system directly integrates with NTUH's PACS and is accessible across departments, including gastroenterology, surgery, and oncology. More... |
| TTY Biopharm and Lotus Pharmaceuticals report good news on cancer drugs 26 May, 2025 Two major local pharmaceutical companies have made progress in entering Taiwan's cancer treatment market. On May 26, TTY Biopharm (TW: 4105) announced that starting June 1 the National Health Insurance Administration will officially reimburse the combination therapy of its chemotherapy drug Pembrolizumab with Pemetrexed. And Lotus Pharmaceuticals (TW: 1795) also announced that its self-developed second-generation tyrosine kinase inhibitor (TKI), bosutinib, used to treat chronic myeloid leukemia (CML), has received market approval from the TFDA. According to IQVIA data, Taiwan's CML treatment market was valued at approximately US$100 million in 2023. More... (in Chinese) |
| StemCyte Biotechnology receives three FDA accelerated designations for its Long COVID drug 26 May, 2025 StemCyte Biotechnology (TW: 4178) announced that its umbilical cord blood cell drug REGENECYTE for treating Long COVID has received three key accelerated designations from the US FDA, including RMAT (Regenerative Medicine Advanced Therapy) designation, compassionate use billing authorization, and direct qualification to apply for a pivotal Phase III clinical trial, establishing it as a global leader in cell therapy for Long COVID treatment. More... (in Chinese) |
| BenQ Dialysis partners with Compassion Veterinary Hospital to establish Taiwan's first animal hemodialysis center 26 May, 2025 BenQ Dialysis, the domestic artificial kidney brand under the BenQ Qisda Group, has officially announced its partnership with Compassion Veterinary Hospital to establish Taiwan’s first animal hemodialysis center. This collaboration introduces cutting-edge technology to the field of critical care for animals, enabling more animals to receive timely and effective medical treatment. With this move, BenQ Dialysis becomes the only leading enterprise in Taiwan engaged in both human and veterinary hemodialysis care. More... (in Chinese) |
| National Taiwan University Hospital fully deploys pancreatic cancer imaging AI 26 May, 2025 National Taiwan University Hospital has recently launched a new AI-powered diagnostic imaging service for pancreatic cancer. Offered as a self-pay service at the NTUH Department of Medical Imaging since late 2024, it features an AI system touted as the first of its kind in the world. More... |
| ========================================= |
| Taiwan Bio Industry Organization (Taiwan BIO) Contact: Daisy Tsai Tel: +886 2 27836028 ext 14 FAX : +886 2 27836027 Mobile: +886 933-139647 | Line ID : daisy222 Email: daisy@taiwanbio.org.tw BIO Asia-Taiwan 2025 (23-27 July, 2025) ========================================= Taiwan Bio Industry Organization (Taiwan BIO) Room C229, Bldg. C, No.99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei, Taiwan (11571) ========================================= |